Differential expression of microRNAs in plasma of colorectal cancer patients: A potential marker for colorectal cancer screening. Export

@article{citeulike:4434628, abstract = {OBJECTIVE: MicroRNAs (miRNAs) have been shown to anticipate great cancer diagnostic potential. We investigated whether plasma miRNAs could discriminate patients with and without colorectal cancer (CRC). METHODS: This study was divided into three phases: (i) Marker discovery using real-time PCR-based miRNA profiling on plasma, corresponding cancerous and adjacent non-cancerous colonic tissues of 5 CRC patients, along with plasma from 5 healthy individuals as controls. (ii) Marker selection and validation by real-time quantitative RT-PCR on a small set of plasma. (iii) Independent validation on a large set of plasma from 90 CRC patients, 20 gastric cancer patients, 20 patients with inflammatory bowel disease (IBD) and 50 healthy controls. RESULTS: Of the panel of 95 miRNAs analyzed, 5 miRNAs were up-regulated both in plasma and tissue samples. All the 5 miRNAs were validated on the plasma of 25 CRC patients and 20 healthy controls. Both miR-17-3p and miR-92 were significantly elevated in CRC patients (p<0.0005). The plasma levels of these markers were significantly reduced after surgery in 10 CRC patients (p<0.05). Further validation with an independent set of plasma samples (n=180) indicated that miR-92 differentiates CRC from gastric cancer, IBD and normal subjects. This marker yielded a receiver operating characteristic curve area of 88.5\%. At a cutoff of 240 (relative expression in comparison to RNU6B snRNA), the sensitivity was 89\% and the specificity was 70\% in discriminating CRC from control subjects. CONCLUSION: MiR-92 is significantly elevated in plasma of CRC patients and can be a potential noninvasive molecular marker for CRC screening.}, author = {Ng, Enders Ko K. and Chong, Wilson Ws W. and Jin, Hongchuan and Lam, Emily Ky K. and Shin, Vivian Y Y. and Yu, Jun and Poon, Terence C W C. and Ng, Simon Sm S. and Sung, Joseph J Y J.}, citeulike-article-id = {4434628}, citeulike-linkout-0 = {http://dx.doi.org/10.1136/gut.2008.167817}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/19201770}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=19201770}, day = {9}, doi = {10.1136/gut.2008.167817}, issn = {1468-3288}, journal = {Gut}, keywords = {colon\_cancer, mir17-92, mirna}, month = {February}, posted-at = {2009-04-29 15:59:32}, priority = {2}, title = {Differential expression of microRNAs in plasma of colorectal cancer patients: A potential marker for colorectal cancer screening.}, url = {http://dx.doi.org/10.1136/gut.2008.167817}, year = {2009} }

TY - JOUR ID - citeulike:4434628 L3 - citeulike-article-id:4434628 N2 - OBJECTIVE: MicroRNAs (miRNAs) have been shown to anticipate great cancer diagnostic potential. We investigated whether plasma miRNAs could discriminate patients with and without colorectal cancer (CRC). METHODS: This study was divided into three phases: (i) Marker discovery using real-time PCR-based miRNA profiling on plasma, corresponding cancerous and adjacent non-cancerous colonic tissues of 5 CRC patients, along with plasma from 5 healthy individuals as controls. (ii) Marker selection and validation by real-time quantitative RT-PCR on a small set of plasma. (iii) Independent validation on a large set of plasma from 90 CRC patients, 20 gastric cancer patients, 20 patients with inflammatory bowel disease (IBD) and 50 healthy controls. RESULTS: Of the panel of 95 miRNAs analyzed, 5 miRNAs were up-regulated both in plasma and tissue samples. All the 5 miRNAs were validated on the plasma of 25 CRC patients and 20 healthy controls. Both miR-17-3p and miR-92 were significantly elevated in CRC patients (p<0.0005). The plasma levels of these markers were significantly reduced after surgery in 10 CRC patients (p<0.05). Further validation with an independent set of plasma samples (n=180) indicated that miR-92 differentiates CRC from gastric cancer, IBD and normal subjects. This marker yielded a receiver operating characteristic curve area of 88.5%. At a cutoff of 240 (relative expression in comparison to RNU6B snRNA), the sensitivity was 89% and the specificity was 70% in discriminating CRC from control subjects. CONCLUSION: MiR-92 is significantly elevated in plasma of CRC patients and can be a potential noninvasive molecular marker for CRC screening. JF - Gut SN - 1468-3288 TI - Differential expression of microRNAs in plasma of colorectal cancer patients: A potential marker for colorectal cancer screening. KW - colon_cancer KW - mir17-92 KW - mirna AU - Ng, Enders Ko AU - Chong, Wilson Ws AU - Jin, Hongchuan AU - Lam, Emily Ky AU - Shin, Vivian Y AU - Yu, Jun AU - Poon, Terence C W AU - Ng, Simon Sm AU - Sung, Joseph J Y PY - 2009/02/09/ UR - http://dx.doi.org/10.1136/gut.2008.167817 ER -